Brain Tumors

Search

Home
Drug Development Services for Brain Tumors
Brain Tumor Targeted Therapeutic Development Services
Drug Development of Brain Tumors Targeting EGFR

Drug Development of Brain Tumors Targeting EGFR

Tumor cells

Targeting tumor and tumor vascular specific markers is a good strategy to control brain tumor growth. The epidermal growth factor receptor (EGFR) is a single-chain transmembrane glycoprotein with a molecular weight of 17 kD, which itself has protein kinase activity and forms part of the cellular signaling system. EGFR is frequently amplified and mutated in human gliomas but is poorly expressed or undetectable in normal brains. This has very important implications for the development of brain tumors as well as for diagnosis and treatment.

We offer drug development services to target EGFR for brain tumors

EGFR is often overexpressed and out of control in brain tumors and is, therefore, a hot topic for brain tumor diagnostic and therapeutic research. Alfa Cytology provides drug development services for brain tumors targeting EGFR. We are also developing EGFR-targeting nanotechnology approaches for drug delivery, as well as antibodies targeting extracellular EGFR and potential anti-EGFR antibody-drug conjugates, to provide new avenues for brain tumor treatment.

Drug type	EGFR tyrosine kinase inhibitor (EGFR-TKI)	Monoclonal antibodies (MAb)
Mechanism of action	Inhibits tyrosine kinase activity and downregulates EGFR activity by competitively binding to ATP in the tyrosine kinase hydrolysis gene. Its sensitivity is associated with mutations in exon 19 or exon 21 of EGFR.	Bind directly to ligands and block the receptor activation caused by ligand-receptor binding thereby downregulating EGFR activity. Anti-EGFR MAb drugs can block tumor cell cycle progression, accelerate apoptosis, inhibit tumor angiogenesis, inhibit tumor infiltration and metastasis, and enhance the effects of radiotherapy.
Target	EGFR EGFR/HER2 EGFR/EGFRvIII Carbohydrate antigen (CA) 19-9 Glioma stem cells (GSCs)
Drug development services	Alfa Cytology is assisting customers in the development of reversible EGFR mutation inhibitors that can penetrate the blood-brain barrier, primarily to increase free drug concentrations in the cerebrospinal fluid and blood. In addition, the human EGFR variant III (EGFRvIII), a mutant isoform of EGFR, is also being developed as a potential molecular target for the specific delivery of diagnostic and therapeutic agents to brain tumors.	Alfa Cytology is assisting customers in redirecting T cells to EGFRvIII-expressing tumors, allowing antibodies to effectively kill EGFRvIII-expressing brain tumors. We are also focusing our brain tumor drug development services on therapeutic MAb targeting the growth factor pathway.

EGFR-targeted anti-brain tumor therapy has become one of the very active areas of brain tumor research. Alfa Cytology is constantly working to advance newer iterations of EGFR-targeting, and we hope to provide therapeutic opportunities for patients with EGFR-targeted brain tumors through reconfigured. Please contact us for the latest news on how EGFR-targeted drugs are treating brain tumors.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Online Inquiry

Brain Tumors

Alfa Cytology has been committed to providing comprehensive services and products to our brain tumor research customers worldwide through our global network of operations.